23 Jun 2021
MYND Life Sciences Expands Intellectual Portfolio to Target Alzheimer’s disease and related forms of Dementia with Chemical Subclasses of Psilocybin Analogues
Author: admintech | Filed under: Press ReleaseVANCOUVER, BC, June 23, 2021 /PRNewswire/ – MYND Life Sciences Inc. (CSE: MYND) (“MYND”) a drug research and development company focused on novel psychedelic drug development, diagnostic approaches and pharmaceuticals, is pleased to announce it has expanded its intellectual property…